Landon Capital

IceCure Medical (ICCM), renowned for its innovative cryoablation technology, has announced a noteworthy 26% surge in revenues stemming from sales of its ProSense systems and disposables for the fiscal year concluding on December 31, 2023. Although experiencing a slight decline in gross margin compared to the prior year, largely attributed to reduced revenue from a distribution agreement, IceCure has achieved an impressive 47% increase in non-GAAP gross profit.

Furthermore, the company has achieved a significant milestone by successfully wrapping up its ICE3 clinical study, initiating the FDA marketing clearance process, and gearing up for potential approval, which is anticipated to catalyze global sales. In tandem with these developments, IceCure has unveiled its next-generation XSense system and is diligently preparing for the commercial launch of ProSense in the U.S. market.